The UPV/EHU’s Neurochemistry and Neurodegeneration group has come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. Research shows that the drug activates the cannabinoid neurotransmitter system (which protects the brain), and this stimulates the cholinergic system (which controls memory and learning) by increasing the synthesis of acetylcholine (a neurotransmitter in the brain that controls memory and learning). These results open up a promising therapeutic approach.
Research spanning more than 20 years has led the UPV/EHU’s Neurochemistry and Neurodegeneration group under Dr Rafael Rodríguez-Puertas to discover a promising avenue for the development of new therapies that improve memory in cases of cognitive impairment in neurodegenerative…